Skip to main content

Advertisement

Table 1 IC50s of sorafenib and metapristone on HCC cell lines in vitro. Data are expressed as the mean ± SD (n = 3)

From: Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib

HCC cell lines IC50 (μM)
Sorafenib Metapristone
24H 48H 24H 48H
SMMC-7721 21.87 ± 5.27 10.06 ± 3.69 120.30 ± 21.07 47.24 ± 8.44
HepG2 10.46 ± 2.69 5.93 ± 2.25 118.49 ± 15.28 62.23 ± 9.81
Huh7 13.14 ± 0.63 10.91 ± 0.69 106.06 ± 10.27 69.27 ± 4.55